

CASE STUDY

Enrolling >5,700 Participants for a Global Phase 3 Trial

The Objective

Velocity was selected to deliver a large portion of patients for a global Phase 3 vaccine trial.

- → Global enrollment goal: 40,000 participants across > 300
- → Velocity enrollment goal: 5,435 participants (13.5% of trial) across 35 sites (31 U.S., 3 Germany, 1 U.K.)
- → Target population: Adults aged ≥50, stratified into three age groups
- → Enrollment window: September to November 2024

The Result

Velocity achieved its enrollment goal in mid-November, 11 days before the enrollment window closed. Given this success, Velocity was authorized to enroll beyond its initial target.

Three Velocity sites, equipped with on-site peripheral blood mononuclear cell (PBMC) collection, processing, and analysis capabilities, handled a subset of 200 participants requiring PBMC services.

Velocity enrolled >5,700 participants (14.5% of the trial; 106.5% of the initial target). Compared to other trial sites, Velocity delivered an average of >30% more participants per site.

Velocity's contribution underscored its ability to exceed ambitious enrollment goals, reflecting its operational excellence and ability to scale effectively in global trials.

The Trial

Client: Large pharma Sponsor

Trial: A multinational Phase 3 vaccine trial

Target population: Adults aged ≥50, stratified into three age groups

Velocity Sites

United States

- Anderson, SC
- Banning, CA (Now San Bernardino)
- Baton Rouge, LA
- Binghamton, NY
- Boise, ID
- Cincinnati, OH (Blue Ash)
- Cincinnati, OH (Mt. Auburn)
- Columbia, SC
- Gaffney, SC
- Grand Island, NE
 Spokane, WA
- Hampton, VA
- Huntington Park, CA
 Union, SC
- Lafayette, LA
- Lincoln, NE
- Los Angeles, CA (Westlake)

- Mobile, AL
- New Orleans, LA
- Norfolk, NE
- Omaha, NE
- Portsmouth, VA
- Providence, RI
- Rockville, MD
- San Diego, CA
- Santa Ana, CA Savannah, GA
- Sioux City, IA
- Syracuse, NY

 - Valparaiso, IN
 - Vestal, NY

Germany

- Berlin
- Hamburg
- Leipzig

United Kingdom

North London